Analysts on Wall Street project that Moderna (MRNA) will announce quarterly loss of $2.65 per share in its forthcoming report, representing a decline of 581.8% year over year. Revenues are projected ...

Looking ahead, BofA cut its 2025 and 2026 revenue forecasts by 18% and 15%, respectively. While negative EPS projections ...

BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $34 from $41 and keeps an Underperform rating on the shares ...

(CN) — A federal judge has temporarily blocked an expected $4 billion slash to funding for biomedical research after a group ...

(CN) — A coalition of 22 state attorneys general is taking aim at a Trump administration policy that would slash funding for ...

Janney Montgomery Scott LLC lowered its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 21.0% in the fourth quarter, ...

O n Friday, February 7, a hearing took place in the Montana state legislature on a bill that would ban the use of mRNA vaccines in humans. The bill was sponsored by State Representative Greg Kmetz ...

We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

To come up with last week’s worst performers, we considered only the stocks with at least $2 billion in market capitalization ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

Inflation data, Powell testimony, more earnings will be in focus this week. • Robinhood’s strong financial health, robust ...